What is TrenibotE
Neuromodulators have emerged as the leading choice for cosmetic procedures worldwide, primarily due to their remarkable efficacy in facial rejuvenation. As we age, our skin undergoes various changes, with fine lines and wrinkles often appearing due to repetitive facial expressions—such as smiling, frowning, or squinting. These visible signs of aging can profoundly affect our appearance, leading many to feel and appear older than their actual age. If you notice these preliminary signs of aging or are proactive about preserving your youthful look, neuromodulator treatments, commonly known as Botox (scientifically as onabotulinumtoxinA), may be the ideal non-invasive solution. Dr. Michele Green has distinguished herself as one of the first board-certified dermatologists in New York City to offer neuromodulator injections. With extensive experience and a meticulous eye for aesthetics, he has earned a stellar reputation for delivering what many clients consider the “best Botox in New York City.” Whether you aim to reduce the appearance of existing wrinkles or prevent future ones, a consultation with Dr. Green can guide you toward achieving the smooth, radiant skin you desire. With a tailored approach to each individual’s needs, you can feel confident in exploring the possibilities of neuromodulator treatments and their potential to enhance your natural beauty.
AbbVie, a leading pharmaceutical company known for its advancements in aesthetic treatments, recently introduced an innovative neuromodulator injection, TrenibotE, which stands for trenibotulinumtoxinE. This cutting-edge product is specifically formulated for the glabella—the area between the eyebrows, which is prone to frown lines from repetitive facial expressions. TrenibotE stands out in the cosmetic market for its notably faster onset of action, enabling patients to achieve visible results more quickly than with traditional neuromodulator options. New patients can anticipate noticeable improvements in a shorter timeframe, making it an appealing choice for those seeking prompt aesthetic enhancement. However, it is important to note that TrenibotE’s efficacy is relatively short-lived, requiring more frequent treatments to sustain the desired look. This could mean scheduling appointments every few months rather than the longer intervals typically associated with other neuromodulator treatments. Suppose you are looking to smooth fine lines and wrinkles or enhance your overall appearance. In that case, it is best to schedule a consultation with Dr. Green to determine whether neuromodulator injections are a good treatment for you and to get her guidance on developing a skincare routine tailored to your skin type, further increasing the likelihood of achieving a glowy, youthful complexion.
Dr. Michele Green is a highly esteemed Allergan platinum injector of neuromodulators, based in the heart of New York City. With over 25 years of dedicated experience in cosmetic dermatology, she has established herself as a leading authority on cosmetic injectables and non-invasive facial treatments. Dr. Green is particularly renowned for her expertise in administering neuromodulator injections to achieve balanced facial aesthetics and smooth out fine lines and wrinkles. Dr. Green’s commitment to excellence has garnered her recognition from several prestigious sources, including Castle Connolly, Super Doctors, The New Yorker, and The New York Times, where she is frequently celebrated as one of New York City’s top dermatologists. Emphasizing a “less is more” philosophy, Dr. Green skillfully crafts subtly transformative outcomes that leave her patients looking refreshed and rejuvenated without appearing overdone. Her distinctive approach to neuromodulator application is meticulously tailored to each individual’s anatomy and desired aesthetic, ensuring results that enhance rather than alter a patient’s natural contours. Through her innovative techniques, extensive experience, and heartfelt dedication, Dr. Michele Green continues to set the standard for excellence in cosmetic dermatology across New York City, influencing both the industry and her patients’ lives.
What is TrenibotE?
TrenibotE represents a pivotal advancement in the realm of aesthetic treatments as a first-in-class botulinum neurotoxin serotype E. AbbVie developed TrenibotE to target moderate-to-severe glabellar lines, commonly known as frown lines, which can significantly contribute to an aged or fatigued appearance. Distinguished by its rapid onset of action, patients may begin to notice results as early as 8 hours post-administration, compared with traditional neuromodulators like Botox, which typically require up to 2 weeks for full effects to become evident. TrenibotE also has a shorter duration of effect, which lasts approximately 2-3 weeks. While this may require more frequent treatment sessions to maintain the desired aesthetic, it appeals to patients who prefer an immediate outcome over a prolonged treatment cycle. In addition to its efficacy, TrenibotE also addresses a key concern for many potential patients—namely, the fear of achieving an unnatural or “frozen” look associated with cosmetic procedures. Dr. Cheryl Burgess, MD, FAAD, the lead clinical investigator for one of the Phase 3 studies, highlighted this barrier, stating, “concern about an unnatural outcome remains a significant barrier for many patients considering medical aesthetic treatments.” She believes TrenibotE could help overcome this barrier, noting that “a product offering rapid onset of effect and a short duration of action could help mitigate this concern, thereby empowering patients to explore their aesthetic treatment journey with confidence.” Overall, TrenibotE stands out as a promising solution for individuals seeking effective, swift wrinkle reduction, with its unique combination of rapid onset and a manageable duration of effect, paving the way for a more dynamic approach to aesthetic enhancement.
Who makes Trenibote?
In April 2025, AbbVie, the parent company of Allergan Aesthetics—widely recognized for its flagship product, Botox cosmetics—announced a groundbreaking development that could reshape the landscape of cosmetic and aesthetic treatments. The company revealed that it had officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for TrenibotE, an innovative new neuromodulator designed to enhance both medical and aesthetic procedures. TrenibotE represents the forefront of neuromodulation research, aiming to offer advanced therapeutic solutions for a variety of conditions, from facial wrinkles to more complex medical issues. AbbVie emphasizes that TrenibotE’s development is grounded in cutting-edge science and extensive clinical studies, ensuring patient safety and efficacy.
Is TrenibotE safe?
TrenibotE is a neuromodulator currently in development for treating fine lines and wrinkles, developed by the well-established company AbbVie, known for its commitment to safety in cosmetic products, including the widely recognized Botox. Currently, TrenibotE has not received FDA approval, placing it in a pre-market status pending regulatory evaluation. As of May 2025, significant progress has been made toward its approval, with the company having completed phase 3 trials, a critical milestone in the drug development process. The Biologics License Application (BLA) for TrenibotE has been bolstered by comprehensive data derived from a clinical program involving over 2,100 patients. This program comprises two pivotal Phase 3 studies evaluating the efficacy of TrenibotE for the treatment of moderate-to-severe glabellar lines, commonly known as frown lines between the eyebrows. In addition, a Phase 3 open-label safety study was conducted to further assess its safety profile. Remarkably, all primary and secondary endpoints established for these studies were successfully met. Importantly, treatment-emergent adverse events associated with TrenibotE were comparable to those experienced by patients receiving placebo, both after a single treatment and after up to 3 consecutive treatments. Topline results from these pivotal studies have previously been disseminated, indicating a promising, safe future for TrenibotE in the aesthetics sector.
Is TrenibotE legit?
Yes! TrenibotE is legit as it is developed by AbbVie, a prominent biopharmaceutical company and the parent organization of Allergan Aesthetics. This innovative product is designed to enhance cosmetic procedures by offering rapid results, distinguishing itself from traditional injections like Botox. TrenibotE utilizes neuromodulators containing botulinum serotype A, providing patients with noticeable improvements in appearance in less time. Currently, TrenibotE remains pending FDA approval and is undergoing extensive clinical trials, currently in phase 3, to evaluate its safety and efficacy. Darin Messina, Senior Vice President of AbbVie, expressed optimism about the approval process, emphasizing the potential of TrenibotE to become a valuable addition to the portfolio of cosmetic treatments once it receives regulatory approval.
Is TrenibotE better than Botox?
Developed by AbbVie, TrenibotE is notable for being the first neuromodulator derived from botulinum neurotoxin serotype E. In contrast, other well-known products such as Botox, Dysport, Xeomin, Jeuveau, and Daxxify are formulated with botulinum neurotoxin serotype A, whereas Myobloc is formulated with serotype B. These serotypes represent variations of the botulinum toxin produced by specific Clostridial species, each with different effects on human physiology. Although no single product can be definitively labeled as superior to the others, each neuromodulator has distinct characteristics that may make it more suitable for certain individuals or treatment goals. For example, while TrenibotE is not yet FDA-approved for treating fine lines and wrinkles, it is described as fast-acting, with noticeable results emerging just a few hours after injection—a potential advantage for those seeking quicker improvements. To determine the most appropriate treatment for your needs, it is essential to consult a qualified, board-certified dermatologist, such as Dr. Michele Green. An expert in dermatologic procedures, Dr. Green can provide guidance on whether TrenibotE is right for you and ensure that any injections are performed with precision to minimize the risk of side effects.
How to get started with your neurotoxin treatment today
If you are contemplating a non-surgical cosmetic treatment to diminish fine lines and wrinkles on your face, neuromodulators may be an ideal solution. These injectable treatments, which include popular options like Botox, Dysport, and Xeomin, work by temporarily ‘freezing’ and relaxing specific facial muscles. This process helps reduce unwanted muscle contractions, which are primarily responsible for the formation of dynamic wrinkles and lines—those most noticeable when we express emotions such as smiling or frowning. Given the myriad of neuromodulator options available, it is recommended to consult with a board-certified dermatologist like Dr. Michele Green, who can provide a tailored treatment plan that aligns with your unique anatomy and aesthetic goals. Located in the heart of New York City, Dr. Green is recognized for her artistic touch and deep understanding of facial structure, ensuring that your results not only look natural but also contribute to a refreshed and youthful appearance that lasts.
Dr. Michele Green brings over 25 years of experience in dermatology and is highly regarded for her expertise in non-invasive cosmetic treatments, including neuromodulator injections. Renowned for her ‘less-is-more’ approach to facial rejuvenation, Dr. Green emphasizes the importance of customizing each treatment plan to cater to the specific needs and desires of her patients. This personalized strategy enables her to achieve optimal results while preserving the patient’s natural expression and character. Her commitment to excellence has earned her consistent recognition as one of NYC’s top dermatologists by esteemed publications such as Super Doctors, New York Magazine, and Castle Connolly. If you are curious about whether Botox is a good fit for you, we invite you to reach out to our NYC office today. You can also call us at 212-535-3088 to discuss the potential benefits of neuromodulators and the possibility of combining them with dermal fillers like Juvederm, Sculptra, or Restylane. Together, these treatments can enhance your overall aesthetic and rejuvenate your complexion, offering a comprehensive approach to beauty that maximizes the impact of cosmetic interventions.